Skip to content

Author

L. Greillier

6 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

AB008. Final analysis from PECATI phase 2 trial: lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma

Background There is no standard second-line treatment for patients with platinum refractory advanced B3-Thymoma (T) and thymic carcinoma (TC). In this population, the PECATI trial testing lenvatinib plus pembrolizumab met its primary endpoint, with 5-month progression-free survival (PFS) of 88.0% (90% CI: 73.5–94.8). M...

Jordi Remon, Paolo Bironzo, Nicolas Girard et al. · 0 citations
Open access Oct 2026

Real-world outcomes of caucasians with EGFR -mutated non-small-cell lung cancer treated with surgery (EXERPOS-2 GFPC study)

Little is known about the natural history of epidermal growth factor receptor ( EGFR) -mutated non-small-cell lung cancer (NSCLC) in Caucasian patients treated with surgery before the generalization of adjuvant treatment with osimertinib. The primary objective of this study was to describe the outcomes...

J. Auliac, P. Thomas, O. Bylicki et al. · 0 citations
Review Open access Oct 2026

Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020).

BACKGROUND Pembrolizumab, alone or combined with platinum-based chemotherapy, is a standard first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) without actionable oncogenic alterations and with high programmed death-ligand 1 (PD-L1) expression. We conducted a head-to-head comparison of...

R. Descourt, A. Mogenet, Maelys Consigny et al. · 0 citations
Open access Sep 2026

First round of lung cancer screening among patients with atheromatous cardiovascular disease exposed to tobacco: a prospective cohort study.

INTRODUCTION Identification of populations eligible for lung cancer screening (LCS) is a priority question in this field. The primary objective of this study was to quantify lung cancer prevalence after a first round of LCS among patients with history of atheromatous cardiovascular disease (aCVD) and tobacco exposure....

E. Armand, C. Buton, C. Caramella et al. · 0 citations
Open access Sep 2026

Outcomes of long-term responders to immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). A retrospective regional study.

BACKGROUND For advanced lung cancer patients, an increasing number of long responders to Immune Checkpoint Inhibitors (ICI) is observed. Thus, the optimal treatment duration remains unclear whereas indefinite treatment is associated to immune-related adverse events (irAEs) and financial burden. OBJECTIVE To describe...

Arnaud De Gunten, A. Mogenet, A. Bronstein et al. · 0 citations
Open access Aug 2026

Tolerance and Efficacy of Targeted Therapies After Immunotherapy for Advanced Non-Small Cell Lung Cancers Harboring Oncogenic Alterations: The GFPC-TOXIMAD Study

Simple Summary In patients with advanced lung cancer harboring targetable gene mutations, sequential immunotherapy-targeted therapy was associated with higher rate of adverse events. A short delay between last immunotherapy administration and targeted therapy administration may increase the risk of serious adverse even...

Thomas Pierret, J. Auliac, C. Ricordel et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.